Experimental ALS drug RJK002 enters first human safety trial
Disease control
Ongoing
This early-stage study tests whether a single injection of RJK002 into the spinal fluid is safe for people with ALS, a progressive nerve disease. Nine adults with ALS will receive the drug and be monitored for side effects and changes in daily function. The goal is to find a safe…
Phase: PHASE1 • Sponsor: RJK Biopharma Ltd • Aim: Disease control
Last updated May 11, 2026 20:37 UTC